Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3(+) tumour-infiltrating lymphocytes (TIL) from patients with ovarian an...

Yazar: Melichar, B, Nash, M A, Lenzi, R, Platsoucas, C D, Freedman, R S
Baskı/Yayın Bilgisi 2000

P-153 Regorafenib in the real-life clinical practice: data from the czech registry

Yazar: Buchler, T., Bortlicek, Z., Hejduk, K., Melichar, B., Pokorna, P., Linke, Z., Petruželka, L., Finek, J., Prausova, J., Kubáčková, K.
Yayımlandı Ann Oncol (2016)

Role of CCND1 and C-MYC oncogenes in metastatic breast cancer patients treated by herceptin

Yazar: Trojanec, R, Koudelakova, V, Bouchalova, K, Radova, L, Ondryasova, H, Krejci, E, Megova, M, Cizkova, M, Mlcochova, S, Melichar, B, Hajduch, M
Baskı/Yayın Bilgisi 2011

BCL2 is a predictive marker of adjuvant CMF regimen in triple-negative breast cancer patients

Yazar: Bouchalova, K, Cizkova, M, Trojanec, R, Koudelakova, V, Radova, L, Furstova, J, Melichar, B, Cwiertka, K, Kharaishvili, G, Kolar, Z, Hajduch, M
Baskı/Yayın Bilgisi 2011

P-005 Prognostic significance of the frequency of primary cilia in cells of small bowel and colorectal adenocarcinoma

Yazar: Kupec, M., Dvorak, J., Hadzi Nikolov, D., Dusek, L., Filipova, A., Richter, I., Buka, D., Ryska, A., Mokry, J., Filip, S., Melichar, B., Buchler, T., Abrahamova, J.
Yayımlandı Ann Oncol (2016)

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer

Yazar: Adiwijaya, BS, Kim, J, Lang, I, Csõszi, T, Cubillo, A, Chen, J‐S, Wong, M, Park, JO, Kim, JS, Rau, KM, Melichar, B, Gallego, JB, Fitzgerald, J, Belanger, B, Molnar, I, Ma, WW
Yayımlandı Clin Pharmacol Ther (2017)

Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial

Yazar: Melichar, B, Casado, E, Bridgewater, J, Bennouna, J, Campone, M, Vitek, P, Delord, J-P, Cerman, J, Salazar, R, Dvorak, J, Sguotti, C, Urban, P, Viraswami-Appanna, K, Tan, E, Tabernero, J
Baskı/Yayın Bilgisi 2011

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer

Yazar: Deplanque, G., Demarchi, M., Hebbar, M., Flynn, P., Melichar, B., Atkins, J., Nowara, E., Moyé, L., Piquemal, D., Ritter, D., Dubreuil, P., Mansfield, C. D., Acin, Y., Moussy, A., Hermine, O., Hammel, P.
Yayımlandı Ann Oncol (2015)

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses

Yazar: Brodowicz, T, Lang, I, Kahan, Z, Greil, R, Beslija, S, Stemmer, S M, Kaufman, B, Petruzelka, L, Eniu, A, Anghel, R, Koynov, K, Vrbanec, D, Pienkowski, T, Melichar, B, Spanik, S, Ahlers, S, Messinger, D, Inbar, M J, Zielinski, C
Yayımlandı Br J Cancer (2014)

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the panc...

Yazar: Fuchs, C. S., Azevedo, S., Okusaka, T., Van Laethem, J.-L., Lipton, L. R., Riess, H., Szczylik, C., Moore, M. J., Peeters, M., Bodoky, G., Ikeda, M., Melichar, B., Nemecek, R., Ohkawa, S., Świeboda-Sadlej, A., Tjulandin, S. A., Van Cutsem, E., Loberg, R., Haddad, V., Gansert, J. L., Bach, B. A., Carrato, A.
Yayımlandı Ann Oncol (2015)

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Yazar: Motzer, R.J., Tannir, N.M., McDermott, D.F., Frontera, O. Arén, Melichar, B., Choueiri, T.K., Plimack, E.R., Barthélémy, P., Porta, C., George, S., Powles, T., Donskov, F., Neiman, V., Kollmannsberger, C.K., Salman, P., Gurney, H., Hawkins, R., Ravaud, A., Grimm, M.-O., Bracarda, S., Barrios, C.H., Tomita, Y., Castellano, D., Rini, B.I., Chen, A.C., Mekan, S., McHenry, M.B., Wind-Rotolo, M., Doan, J., Sharma, P., Hammers, H.J., Escudier, B.
Yayımlandı N Engl J Med (2018)